Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors [PDF]
Pulmonary Circulation, 2020 Adherence to therapy for pulmonary arterial hypertension is essential to optimize patient outcomes, but data on real-world adherence to different pulmonary arterial hypertension drug classes are limited.
Robert P. Frantz +6 more
doaj +3 more sources
Endothelin Receptor Antagonists in Kidney Disease. [PDF]
Int J Mol Sci, 2023 Endothelin (ET) is found to be increased in kidney disease secondary to hyperglycaemia, hypertension, acidosis, and the presence of insulin or proinflammatory cytokines.
Martínez-Díaz I +7 more
europepmc +5 more sources
Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand? [PDF]
Vascular Health and Risk Management, 2018 Michele Correale,1 Armando Ferraretti,2 Ilenia Monaco,3 Davide Grazioli,1 Matteo Di Biase,4 Natale Daniele Brunetti3 1Department of Cardiology, Ospedali Riuniti University Hospital, Foggia, 2Cardiology Unit, “Caduti in guerra” Hospital ...
Correale M +5 more
doaj +3 more sources
Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond? [PDF]
Nephrology (Carlton), 2023 The burden of chronic kidney disease is increasing worldwide, largely due to the increasing global prevalence of diabetes mellitus and hypertension.
Chung EYM +3 more
europepmc +2 more sources
Endothelin Receptor Antagonists for Kidney Protection: Lessons from the SONAR Trial.
Clin J Am Soc Nephrol, 2022 The endothelin system has been widely implicated in CKD. Binding of endothelin-1, the effector peptide of the endothelin system, to the endothelin-A receptor causes endothelial glycocalyx damage, glomeruloscle-rosis, and podocyte injury and activates ...
Heerspink HJL, de Zeeuw D.
europepmc +2 more sources
Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy. [PDF]
J Clin Med, 2020 The endothelin axis, recognized for its vasoconstrictive action, plays a central role in the pathology of pulmonary arterial hypertension (PAH). Treatment with approved endothelin receptor antagonists (ERAs), such as bosentan, ambrisentan, or macitentan,
Enevoldsen FC +5 more
europepmc +2 more sources
Endothelin receptor antagonists in diabetic and non-diabetic chronic kidney disease. [PDF]
Clin Kidney JChronic kidney disease (CKD) is one of the major causes of morbidity and mortality, affecting >800 million persons globally. While we still lack efficient, targeted therapies addressing the major underlying pathophysiologic processes in CKD, findings of ...
Ivković V, Bruchfeld A.
europepmc +2 more sources
The role of endothelin receptor antagonists in kidney disease [PDF]
Renal FailureKidney diseases are among the most prevalent conditions worldwide, impacting over 850 million individuals. They are categorized into acute kidney injury and chronic kidney disease. Current preclinical and clinical trials have demonstrated that endothelin
Xiaoting Ma +5 more
doaj +2 more sources
A network meta-analysis for safety of endothelin receptor antagonists in pulmonary arterial hypertension. [PDF]
Cardiovasc Diagn Ther, 2019 Background Currently, direct comparative safety between endothelin receptor antagonists (ERAs) in pulmonary arterial hypertension (PAH) is limited. Thus, a systematic review with network analysis was conducted.
Zhang YJ +8 more
europepmc +2 more sources
Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. [PDF]
PLoS ONE, 2012 Two endothelin receptor antagonists (ERAs), bosentan and ambrisentan, are currently approved for the treatment of pulmonary arterial hypertension (PAH), a devastating disease involving an activated endothelin system and aberrant contraction and ...
John Gatfield +4 more
doaj +2 more sources